华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 变更及终止部分募投项目及募投项目延期的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 北京英诺特生物技术股份有限公司（以下简称"英诺特"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上 海证券交易所科创板股票上市规则》及《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等相关规定，对英诺特变更及终止部分募投项目及 募投项目延期的事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 28 日作出的《关于同意北京英诺特生物技术股份有限公司首次公开发行股票注册的 批复》（证监许可[2022]902 号），并经上海证券交易所同意，公司于 2022 年 7 月 首次向社会公开发行人民币普通股（A 股）股票 34,020,000 股，每股面值人民币 1.00 元，每股发行价为人民币 26.06 元，募集资金总额为人民币 88,656.12 万元， 扣除发行费用（含增值税，不含前期 ...

北京英诺特生物技术股份有限公司 监事会关于公司 2023 年限制性股票激励计划（草案） 的核查意见 北京英诺特生物技术股份有限公司（以下简称"公司"）监事会依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上 市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范性 文件和《公司章程》的有关规定对公司《2023 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）进行审核，发表核查意见如下： 1、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划的 情形，包括： （1）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （2）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； （3）上市后最近 36 个月内出现过未按法律法规、公司章程、公开承诺进行 利润分配的情形； （4）法律法规规定不得实行股权激励的； （ ...

证券代码：688253 证券简称：英诺特 公告编号：2023-027 北京英诺特生物技术股份有限公司关于使用暂时闲 置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2023 年 8 月 27 日召开第一届董事会第十八次会议、第一届监事会第 十五次会议，审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》， 同意公司以不超过人民币 4.3 亿元（含本数）的闲置募集资金进行现金管理，用 于购买安全性高、流动性好的理财产品或存款类产品（包括但不限于协定存款、 通知存款、结构性存款、定期存款、大额存单等），自前次现金管理的授权到期 1 / 6 投资种类：安全性高、流动性好的理财产品或存款类产品（包括但不限 于协定存款、通知存款、结构性存款、定期存款、大额存单等）。 投资金额：不超过人民币 4.3 亿元（含本数）的闲置募集资金进行现金 管理，自前次现金管理的授权到期之日起 12 月内可循环滚动使用，即 2023 年 9 月 2 日至 2024 年 9 月 1 日。 已履行及拟 ...

证券代码：688253 证券简称：英诺特 公告编号：2023-023 北京英诺特生物技术股份有限公司股东集中竞价 减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至 2023 年 8 月 11 日，北京英诺特生物技术股份有限公司（以下简称"公 司"、"发行人"）股东宁波梅山保税港区红杉智盛股权投资合伙企业（有限合伙） （以下简称"红杉智盛"）持有公司股份 11,667,400 股，占公司总股本 8.5751%。 上述股份已于 2023 年 7 月 28 日上市流通，均为公司首次公开发行前取得股 份。 集中竞价减持计划的主要内容 公司于 2023 年 8 月 11 日收到股东红杉智盛的《关于英诺特集中竞价交易减 持计划的告知函》，其拟通过集中竞价方式减持合计不超过 2,721,216 股，即不超 过公司总股本的 2.0000%。红杉智盛通过集中竞价减持的，在任意连续 90 个自 然日内减持的股份总数不超过公司总股本的 1%，减持期间为自本公告披露之日 起 1 ...

证券代码：688253 证券简称：英诺特 公告编号：2023-022 北京英诺特生物技术股份有限公司股东集中竞价 减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 公司于 2023 年 8 月 11 日收到股东苏州新建元及其一致行动人开曼元生的 《关于股份减持计划的告知函》，其拟通过集中竞价方式减持合计不超过 4,080,000 股，即不超过公司总股本的 2.9987%。 其中苏州新建元已通过中国证券投资基金业协会备案，符合《上市公司创业 投资基金股东减持股份的特别规定》和《上海证券交易所上市公司创业投资基金 股东减持股份实施细则》的减持特别规定，其通过集中竞价减持的，在任意连续 60 个自然日内减持的股份总数不超过公司总股本的 1%，减持期间为自本公告披 露之日起 15 个交易日后的 6 个月内；开曼元生通过集中竞价减持的，在任意连 续 90 个自然日内减持的股份总数不超过公司总股本的 1%，减持期间为自本公告 披露之日起 15 个交易日后的 6 个月内。 若公司在本减持计划实 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥134,510,760.91, representing a year-on-year increase of 93.55%[5] - The net profit attributable to shareholders for the same period was ¥53,818,215.08, reflecting a growth of 104.21% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 197.43% to ¥45,956,269.24[5] - Basic earnings per share for Q1 2023 were ¥0.40, up by 52.13% from the previous year[6] - Total operating revenue for Q1 2023 reached CNY 134,510,760.91, a significant increase of 93.8% compared to CNY 69,495,587.09 in Q1 2022[20] - Net profit for Q1 2023 was CNY 53,818,215.08, representing a 104.5% increase from CNY 26,353,868.93 in Q1 2022[21] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.40, compared to CNY 0.26 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 53,818,215.08, compared to CNY 26,353,868.93 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was negative at -¥28,770,855.36, a decline of 320.02% year-on-year[5] - The net cash flow from operating activities was -28,770,855.36, compared to 13,076,633.59 in the previous year, indicating a significant decline in operational performance[24] - The net cash inflow from investment activities was 120,822,998.46, a recovery from a net outflow of -54,848,287.23 in the same period last year[25] - The cash inflow from investment activities totaled 1,105,376,495.33, significantly higher than 55,939,251.38 in the previous year[24] - The cash outflow from operating activities was 90,614,118.03, compared to 78,818,089.63 in the previous year, reflecting increased operational costs[24] - The cash outflow from financing activities was 11,023,130.56, compared to 344,798.20 in the previous year, indicating a rise in financing costs[25] - The company received tax refunds amounting to 3,435,036.98, compared to 506,792.64 in the previous year, showing improved tax recovery[24] - The cash inflow from other operating activities was 6,048,326.24, down from 13,081,049.11 in the previous year, indicating a decrease in operational revenue sources[24] - The company paid 18,729,896.89 in taxes, significantly higher than 6,171,222.97 in the previous year, reflecting increased tax liabilities[24] - The net cash flow from financing activities was -10,997,575.01, compared to 9,655,201.80 in the previous year, indicating a shift towards negative financing cash flow[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,864,911,749.38, down 4.00% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to RMB 1,864,911,749.38, a decrease from RMB 1,942,574,342.50 as of December 31, 2022, reflecting a decline of approximately 4.0%[15] - The company's cash and cash equivalents increased to RMB 456,138,765.13 from RMB 388,670,421.76, representing a growth of about 17.4%[15] - Inventory balance stood at RMB 75,075,863.29, slightly up from RMB 74,795,425.34, indicating a marginal increase of 0.4%[15] - The company reported a total of RMB 977,728,294.17 in trading financial assets, down from RMB 1,114,638,212.12, marking a decrease of approximately 12.3%[15] - The total non-current assets amounted to RMB 207,038,386.81, a slight increase from RMB 205,065,146.22, reflecting a growth of about 0.5%[16] - The company's accounts receivable decreased to RMB 123,451,670.42 from RMB 124,314,691.31, showing a decline of approximately 0.7%[15] - The company has a total of RMB 60,189,321.18 in accounts payable, down from RMB 69,194,598.89, indicating a decrease of about 13.5%[16] - The company’s total current liabilities include RMB 22,843,976.35 in contract liabilities, reflecting a significant reduction from RMB 105,103,823.64[16] - The company has a total of RMB 18,508,225.55 in long-term equity investments, indicating a stable investment strategy[16] Research and Development - R&D investment totaled ¥9,987,729.18, accounting for 7.43% of operating revenue, a decrease of 8.22 percentage points[6] - Research and development expenses for Q1 2023 were CNY 9,987,729.18, slightly down from CNY 10,875,959.08 in Q1 2022[21]

证券代码：688253 证券简称：英诺特 公告编号：2023-015 北京英诺特生物技术股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 04 月 13 日（星期四）下午 15:00-16:00 1 / 3 会议召开时间：2023 年 04 月 13 日（星期四）下午 15:00-16:00 会议召开地点： 上海证券 交易所上证路演中心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 06 日（星期四）至 04 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2022, representing a growth of 15% compared to the previous year[24]. - The company's operating revenue for 2022 was approximately ¥446.62 million, representing a year-over-year increase of 36.62% compared to ¥326.91 million in 2021[25]. - Net profit attributable to shareholders for 2022 was approximately ¥150.68 million, a 25.31% increase from ¥120.25 million in 2021[28]. - The net profit excluding non-recurring gains and losses for 2022 was approximately ¥132.49 million, reflecting a 22.00% increase from ¥108.60 million in 2021[25]. - The company's total assets at the end of 2022 reached approximately ¥1.94 billion, a 143.47% increase from ¥797.87 million at the end of 2021[26]. - The company's net assets attributable to shareholders increased by 128.85% year-over-year, reaching approximately ¥1.69 billion in 2022[28]. - The company achieved a revenue of 447 million yuan in 2022, representing a year-on-year growth of 36.62%[40]. - The company reported a foreign exchange gain of approximately ¥42.65 million in 2022, which accounted for 25.93% of the total profit for the year[28]. - The company reported a significant increase in cash flow from financing activities, totaling CNY 815.78 million, a rise of 1,470.01%[118]. - The company reported a net profit margin of 656.38 million, indicating strong profitability[177]. Research and Development - The company is investing in R&D for new technologies, with a budget allocation of 200 million RMB for the upcoming year, focusing on enhancing diagnostic accuracy[24]. - Research and development expenses accounted for 16.16% of operating revenue in 2022, up from 9.52% in 2021, indicating a significant increase in investment in innovation[27]. - Total R&D expenses increased by 132.00% year-over-year, reaching approximately ¥72.18 million, driven by higher personnel costs and an increase in ongoing projects[82]. - The company has established six major technology platforms, including PCR detection and recombinant protein engineering, to enhance its R&D capabilities[91]. - The company has developed a specific antibody detection technology that reduces non-specific reactions caused by endogenous interfering substances[76]. - The company has been expanding its R&D capabilities since 2020, with a dedicated R&D platform director overseeing new projects[183]. - The company is focusing on expanding its product offerings in the immunodiagnostic field, utilizing advanced detection methods for various diseases[85]. Product Development and Launches - New product launches included a respiratory joint detection kit, which has received regulatory approval and is expected to contribute significantly to future sales[24]. - The company successfully launched new combined detection products for respiratory pathogens, including influenza and norovirus tests[39]. - The company has developed a unique nine-in-one respiratory fluorescence test kit, which detects IgM antibodies for nine different pathogens[50]. - The company has developed a new COVID-19 IgM/IgG antibody test kit that provides a supplementary diagnostic tool for suspected cases with negative nucleic acid tests[51]. - The company is actively pursuing new product development and clinical trials, with several projects in various stages of completion[86]. Market Expansion and Strategy - Market expansion plans include entering three new international markets by the end of 2023, aiming for a 5% market share in each[24]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a target of identifying at least two candidates by mid-2023[24]. - The company plans to expand its marketing network both domestically and internationally, with a focus on establishing overseas marketing centers in Southeast Asia, particularly Thailand[161]. - The company aims to enhance its market position through strategic R&D investments and product development initiatives[82]. - The company plans to enter the European market in the next quarter, targeting a revenue contribution of $20 million in the first year[180]. Corporate Governance and Management - The company has maintained compliance with corporate governance regulations and continuously improved its governance structure[168]. - The company appointed a new independent director in February 2023, enhancing its governance structure[181]. - The company has a diverse board with members holding positions in various sectors, enhancing its strategic insights[187]. - The company has not reported any significant differences in governance compared to regulatory requirements[168]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.624 million RMB[190]. Risks and Challenges - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company faces risks related to macroeconomic conditions and potential impacts from healthcare reforms, which could affect product pricing and sales strategies[111]. - The company is at risk of losing key technical personnel, which could adversely affect its R&D progress and innovation capabilities[99]. - The company has implemented strict quality control processes and obtained various quality certifications, but still faces risks related to product quality management[105]. - The company highlighted financial risks related to currency fluctuations and the potential impact on future performance[140].

Financial Performance - The company's operating revenue for Q3 2022 was ¥60,738,932.35, representing a year-on-year increase of 28.46%[5] - Net profit attributable to shareholders for Q3 2022 reached ¥19,122,888.22, a significant increase of 103.79% compared to the same period last year[5] - Basic earnings per share for Q3 2022 were ¥0.17, up by 83.41% compared to the previous year[6] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥17,837,044.36, showing a growth of 100.40% year-on-year[5] - Total operating revenue for the first three quarters of 2022 reached ¥310,532,891.94, an increase of 17.5% compared to ¥264,373,449.86 in the same period of 2021[20] - Net profit for the third quarter of 2022 was ¥127,691,880.56, representing a 21.8% increase from ¥104,807,601.60 in the same quarter of 2021[22] - The company reported a total profit of ¥141,498,773.22 for the third quarter of 2022, up from ¥120,027,545.15 in the same quarter of 2021[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,778,414,890.73, reflecting a year-on-year growth of 122.89%[6] - As of September 30, 2022, the total assets of the company amounted to ¥1,778,414,890.73, a significant increase from ¥797,873,232.31 at the end of 2021[14] - The total current liabilities reached ¥103,011,407.31, up from ¥52,147,430.34, marking an increase of about 97.5%[17] - Total liabilities increased to ¥112,070,174.03 in Q3 2022 from ¥59,703,304.99 in Q3 2021, reflecting a growth in financial obligations[21] - The total equity attributable to shareholders at the end of the reporting period was ¥1,666,344,716.70, an increase of 125.74% compared to the previous year[6] - Shareholder equity rose to ¥1,666,344,716.70 in Q3 2022, compared to ¥738,169,927.32 in Q3 2021, indicating strong financial health[21] Research and Development - Research and development expenses for Q3 2022 totaled ¥14,363,169.94, which is an increase of 110.81% year-on-year, accounting for 23.65% of operating revenue[6] - Research and development expenses for the third quarter of 2022 amounted to ¥48,474,165.11, significantly higher than ¥22,863,891.32 in the same period last year, indicating a focus on innovation[21] - The company emphasized its commitment to innovation and increased investment in R&D to support future growth[9] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥41,705,251.06, reflecting a decrease of 12.41%[6] - The cash flow from operating activities for the first three quarters of 2022 was ¥269,304,347.99, slightly down from ¥274,384,819.73 in the same period of 2021[25] - The net cash flow from operating activities for Q3 2022 was $41,705,251.06, a decrease of 12.5% compared to $47,612,735.73 in Q3 2021[26] - Total cash inflow from investment activities was $1,132,069,411.74, significantly up from $524,545,392.07 in the previous year, indicating a strong investment recovery[26] - The net cash flow from investment activities was -$924,347,210.40, compared to -$72,752,916.76 in Q3 2021, reflecting increased investment expenditures[27] - Cash inflow from financing activities totaled $837,640,608.04, with a net cash flow of $825,982,889.10, a substantial improvement from -$59,204,089.88 in the same quarter last year[27] - The company reported a total cash outflow from investment activities of $2,056,416,622.14, compared to $597,298,308.83 in the previous year, highlighting aggressive investment strategies[26] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 1.70%, an increase of 0.39 percentage points year-on-year[6] - The company's cash and cash equivalents were reported at ¥469,207,724.00, slightly down from ¥479,743,524.21 at the end of 2021[14] - The trading financial assets surged to ¥983,038,475.22, compared to only ¥87,245,837.05 at the end of 2021, indicating a growth of over 1,000%[14] - Accounts receivable increased to ¥71,063,150.43 from ¥4,129,898.69, reflecting a growth of approximately 1,620%[14] - The company's inventory stood at ¥47,039,747.51, compared to ¥43,627,428.64 in the previous year, showing a growth of approximately 9.3%[16] - Non-current assets totaled ¥163,770,967.47, an increase from ¥150,046,755.56, representing a growth of about 9.3%[16] - The company reported a significant increase in other receivables, which rose to ¥4,014,471.23 from ¥267,225.80, a growth of approximately 1,400%[14] - The company’s long-term equity investments were valued at ¥1,001,147.68, indicating a new investment strategy[16] Strategic Insights - The company has not disclosed any new product developments or market expansion strategies in the current report[14]